Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xenazine tetrabenazine: Phase III data

According to FDA briefing documents, Xenazine missed the primary endpoint in the double-blind, U.S. Phase

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE